Biomedical Engineering Reference
In-Depth Information
184. Sewell KL, Parker KC, Woodworth TG, Reuben J, Swartz W,
Trentham DE. (1993) DAB486IL-2 fusion toxin in refractory
rheumatoid arthritis. Arthritis Rheum. 36, 1223-1233.
185. Moreland LW, Sewell KL, Trentham DE, Bucy RP, Sullivan
WF, Schrohenloher RE, et al. (1995) Interleukin-2 diphtheria
fusion protein (DAB486IL-2) in refractory rheumatoid arthri-
tis. A double-blind, placebo-controlled trial with open-label
extension. Arthritis Rheum. 38, 1177-1186.
186. Frankel A, Liu JS, Rizzieri D, Hogge D. (2008) Phase I
clinical study of diphtheria toxin-interleukin 3 fusion protein
in patients with acute myeloid leukemia and myelodysplasia.
Leuk. Lymphoma 49, 543-553.
187. Garland L, Gitlitz B, Ebbinghaus S, Pan H, de Haan H, Puri
RK, et al. (2005) Phase I trial of intravenous IL-4 pseudom-
onas exotoxin protein (NBI-3001) in patients with advanced
solid tumors that express the IL-4 receptor. J. Immunother.
28, 376-381.
188. Zalcberg JR, Pietersz G, Toohey B, Laird J, Huggins R, Zimet
AS, et al. (1994) A Phase I/II study of the intralesional
injection of ricin-monoclonal antibody conjugates in patients
with hepatic metastases. Eur. J. Cancer 30A, 1227-1231.
189. LoRusso PM, Lomen PL, Redman BG, Poplin E, Bander JJ,
Valdivieso M. (1995) Phase I study of monoclonal antibody-
ricin A chain immunoconjugate Xomazyme-791 in patients
with metastatic colon cancer. Am. J. Clin. Oncol. 18, 307-312.
190. Pai LH, Wittes R, Setser A, WillinghamMC, Pastan I. (1996)
Treatment of advanced solid tumors with immunotoxin
LMB-1: an antibody linked to Pseudomonas exotoxin. Nat.
Med. 2, 350-353.
191. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. (2007)
Immunotoxin treatment of cancer. Annu. Rev. Med. 58,
221-237.
192. Hausner PF, Karp JE, Edelman MJ, Kennedy NL, Tathineni
N, Willingham M, et al. (2003) Phase I study of LMB-9 (B3
(dsFv)-PE38), a recombinant disulfide stabilized anti-Lewis
Y immunotoxin administered by coninuous infusion. Proc.
Am. Soc. Clin. Oncol. 22, 736.
193. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. (2009) Phase I
trial of continuous infusion anti-mesothelin recombinant
immunotoxin SS1P. Clin. Cancer Res. 15, 5274-5279.
194. Weaver M, Laske DW. (2003) Transferrin receptor ligand-
targeted toxin conjugate (Tf-CRM107) for therapy of malig-
nant gliomas. J. Neurooncol. 65, 3-13.
195. Multani PS, O'Day S, Nadler LM, Grossbard ML. (1998)
Phase II clinical trial of bolus infusion anti-B4 blocked ricin
immunoconjugate in patients with relapsed B-cell non-
Hodgkin's lymphoma. Clin. Cancer Res. 4, 2599-2604.
196. Grossbard ML, Fidias P, Kinsella J, O'Toole J, Lambert JM,
Blattler WA, et al. (1998) Anti-B4-blocked ricin: a Phase II
trial of 7 day continuous infusion in patients with multiple
myeloma. Br. J. Haematol. 102, 509-515.
197. Grossbard ML, Gribben JG, Freedman AS, Lambert JM,
Kinsella J, Rabinowe SN, et al. (1993) Adjuvant immuno-
toxin therapy with anti-B4-blocked ricin after autologous
bone marrow transplantation for patients with B-cell non-
Hodgkin's lymphoma. Blood 81, 2263-2271.
198. Scadden DT, Schenkein DP, Bernstein Z, Luskey B, Doweiko
J, Tulpule A, et al. (1998) Immunotoxin combined with
chemotherapy for patients with AIDS-related non-Hodgkin's
lymphoma. Cancer 83, 2580-2587.
199. Ortin M. (2005) Immunotherapy of hematological malignan-
cies: What is new? Ann. Oncol. 16(Suppl 2), ii53-62.
200. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C,
Steinberg SM, et al. (2010) Anti-CD22 immunotoxin RFB4
(dsFv)-PE38 (BL22) for CD22-positive hematologic malig-
nancies of childhood: preclinical studies and Phase I clinical
trial. Clin. Cancer Res. 16, 1894-1903.
201. Lynch TJ. Jr., Lambert JM, Coral F, Shefner J, Wen P, Blattler
WA, et al. (1997) Immunotoxin therapy of small-cell lung
cancer: a Phase I study of N901-blocked ricin. J. Clin. Oncol.
15, 723-734.
202. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. (1999)
Evidence for a structural motif in toxins and interleukin-2 that
may be responsible for binding to endothelial cells and
initiating vascular leak syndrome. Proc. Natl. Acad. Sci.
USA 96, 3957-3962.
203. AndroneAS, HryniewiczK, HudaihedA,Mancini D, Lamanca
J, Katz SD. (2004) Relation of unrecognized hypervolemia in
chronic heart failure to clinical status, hemodynamics, and
patient outcomes. Am. J. Cardiol. 93, 1254-1259.
204. Kinoshita Y, Kasaoka S, Fujita M, Oshima C, Kawamura Y,
Tsuruta R, et al. (2010) Synchronized changes in serum
vascular endothelial growth factor during the clinical course
of chronic systemic capillary leak syndrome. Intern. Med. 49,
791-794.
205. Droder RM, Kyle RA, Greipp PR. (1992) Control of systemic
capillary leak syndrome with aminophylline and terbutaline.
Am. J. Med. 92, 523-526.
206. Staak JO, Glossmann JP, Esser JM, Diehl V, Mietz H, Josting
A. (2003) Thalidomide for systemic capillary leak syndrome.
Am. J. Med. 115, 332-334.
207. Lambert M, Launay D, Hachulla E, Morell-Dubois S, Soland
V, Queyrel V, et al. (2008) High-dose intravenous immuno-
globulins dramatically reverse systemic capillary leak syn-
drome. Crit. Care. Med. 36, 2184-2187.
208. Hall PD, Razzouk BI, Willoughby TE, McLean TW, Frankel
AE. (2002) The majority of children and adolescents with
acute myeloid leukemia have detectable anti-DT388-GMCSF
IgG concentrations, but at concentrations that should not
preclude in vivo activity. J. Pediatr. Hematol. Oncol. 24,
521-526.
209. Davis CG, Datta D. (2008) Modified toxins. PTC Patent
Application, PCT/US08/86858.
210. Thompson J, Hu H, Scharff J, Neville DM. Jr. (1995) An anti-
CD3 single-chain immunotoxin with a truncated diphtheria
toxin avoids inhibition by pre-existing antibodies in human
blood. J. Biol. Chem. 270, 28037-28041.
211. Kageyama T, Ohishi M, Miyamoto S, Mizushima H, Iwa-
moto R, Mekada E. (2007) Diphtheria toxin mutant
CRM197 possesses weak EF2-ADP-ribosyl activity that
potentiates its anti-tumorigenic activity. J. Biochem. 142,
95-104.
Search WWH ::
Custom Search